Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK‐2019, a selective EBNA1 inhibitor
Biomedical Chromatography · 2024
DOI: 10.1002/bmc.5775 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2024. Verfasst von Michael T Davis und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Epstein-Barr Virus Nuclear Antigens. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCR NIH HHS, NCI NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
EBNA1 is an Epstein Barr virus (EBV) protein expressed in all EBV‐associated cancers. EBNA1 plays a critical role in the replication and maintenance of EBV episomes in latently infected cells. VK‐2019 was developed as a highly specific inhibitor of EBNA1 DNA binding activity and is currently in phase 1 development as a treatment for EBV‐associated carcinomas. A sensitive and reliable method was developed to quantify VK‐2019 in human plasma using liquid chromatography with tandem mass spectrometry to perform detailed pharmacokinetic studies. VK‐2019 was extracted from plasma using protein precipitation with acetonitrile. Separation of VK‐2019, two purported metabolites, and the internal standard, VK‐2019–d6, was achieved with a Zorbax XDB C 18 column using a gradient flow over 6 min. VK‐2019 was detected using a SCIEX 4500 triple quadrupole mass spectrometer operating in positive electrospray ionization mode. The assay range was 0.5–500 ng/mL and proved to be accurate and precise. Dilutions of 1:10 were accurately quantified. VK‐2019 was stable in plasma at −70°C for approximately 18 months. The method was applied to assess the total plasma concentrations of VK‐2019 in a patient who received a single and multiple oral daily doses of 120 mg.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA.
- Takeda Pharmaceutical Company, San Diego, California, USA.
- Division of Medical Oncology, Stanford Cancer Center, Stanford University, Stanford, California, USA.
- The Wistar Institute, Philadelphia, Pennsylvania, USA.
- Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
- Division of Clinical Pharmacology, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
ORCID-Profile: Troy E Messick, Michelle A Rudek
Förderung
- NIDCR NIH HHS
- NCI NIH HHS
- NCATS NIH HHS
- NIH HHS
- National Cancer Institute
- National Center for Advancing Translational Sciences
- NIH Office of the Director
Zitieren
APA
Davis, M. T., Anders, N. M., Colevas, A. D., Messick, T. E., & Rudek, M. A. (2024). Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK‐2019, a selective EBNA1 inhibitor. Biomedical Chromatography. https://doi.org/10.1002/bmc.5775
Vancouver
Davis MT, Anders NM, Colevas AD, Messick TE, Rudek MA. Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK‐2019, a selective EBNA1 inhibitor. Biomedical Chromatography. 2024. doi:10.1002/bmc.5775
BibTeX
@article{Davis2024,
author = {Davis, Michael T and Anders, Nicole M and Colevas, A Dimitrios and Messick, Troy E and Rudek, Michelle A},
title = {Validation of a robust and rapid liquid chromatography tandem mass spectrometric method for the quantitative analysis of VK‐2019, a selective EBNA1 inhibitor},
journal = {Biomedical Chromatography},
year = {2024},
doi = {10.1002/bmc.5775}
}
EUVIMED